Content about Human Genome Sciences

January 21, 2013

Drug maker GlaxoSmithKline is seeking Food and Drug Administration approval for a new treatment for Type 2 diabetes, the drug maker said.

LONDON — Drug maker GlaxoSmithKline is seeking Food and Drug Administration approval for a new treatment for Type 2 diabetes, the drug maker said.

GSK announced the submission to the FDA of a regulatory approval application for albiglutide. The drug is not approved in any market yet, and the company plans to also seek approval in the European Union this year.

GSK assumed control of albiglutide with its $3.6 billion acquisition of Human Genome Sciences, announced last July.

December 17, 2012

The Food and Drug Administration has approved a new biotech drug from GlaxoSmithKline for anthrax, the drug maker said.

LONDON — The Food and Drug Administration has approved a new biotech drug from GlaxoSmithKline for anthrax, the drug maker said.

GSK announced the approval of raxibacumab for adults and children who have inhaled Bacillus anthracis. The drug is designed for combination with antibiotics and for preventing inhalational anthrax when alternative therapies aren't available. The drug is the result of a project that Human Genome Sciences, now owned by GSK, began working on in 2001 in response to terrorist anthrax attacks in the United States.

July 16, 2012

British drug maker GlaxoSmithKline will acquire development partner Human Genome Sciences for $3.6 billion, GSK said Monday.

LONDON — British drug maker GlaxoSmithKline will acquire development partner Human Genome Sciences for $3.6 billion, GSK said Monday.

The deal, worth $14.25 per share, would give GSK full ownership of the lupus drug Benlysta (belimumab), as well as albiglutide, an experimental drug for diabetes, and darapladib, an experimental heart disease drug.

June 11, 2012

GlaxoSmithKline again has extended an unsolicited tender offer to acquire Human Genome Sciences.

ROCKVILLE, Md. — GlaxoSmithKline again has extended an unsolicited tender offer to acquire Human Genome Sciences.

HGS, which previously rejected an unsolicited bid from GSK, said the latest bid, which was extended Friday, is a tender offer to acquire all of the outstanding shares of HGS for $13 per share. HGS said that the offer price is inadequate and "does not reflect the value inherent in [the company]."

June 4, 2012

One month after GlaxoSmithKline announced its tender offer to acquire Human Genome Sciences, HGS said Friday that its board of directors has rejected the unsolicited bid.

ROCKVILLE, Md. — One month after GlaxoSmithKline announced its tender offer to acquire Human Genome Sciences, HGS said Friday that its board of directors has rejected the unsolicited bid.

May 11, 2012

GlaxoSmithKline is moving forward with its acquisition of Human Genome Sciences.

LONDON — GlaxoSmithKline is moving forward with its acquisition of Human Genome Sciences.

The drug maker said Thursday that it has commenced its previously announced tender offer to acquire all of the outstanding shares of Human Genome Sciences for $13.00 per share in cash, a premium of 81% to HGS's closing share price of $7.17 per share on April 18, the last trading day before HGS publicly disclosed GSK's private offer.

April 25, 2012

GlaxoSmithKline said its offer to buy Human Genome Sciences was "full and fair" Wednesday after HGS turned it down last week, according to published reports.

NEW YORK — GlaxoSmithKline said its offer to buy Human Genome Sciences was "full and fair" Wednesday after HGS turned it down last week, according to published reports.

Reuters reported that GSK's $13-per-share, $2.6 billion offer for HGS would give the former full control of Benlysta (belimumab), the first new drug approved by the Food and Drug Administration for lupus in more than half a century. The two companies developed the drug together under a partnership, and the drug received approval in March 2011.

November 16, 2010

A decision by a Food and Drug Administration advisory committee could pave the way for...

ROCKVILLE, Md. A decision by a Food and Drug Administration advisory committee could pave the way for the first new drug to treat lupus in decades.

 

The FDA’s Arthritis Advisory Committee voted 13-2 Tuesday to recommend approval for Benlysta (belimumab), a drug for systemic lupus erythematosus made by British drug maker GlaxoSmithKline and U.S.-based Human Genome Sciences, the two companies announced. Lupus is an inflammatory disorder that affects internal organs, joints and skin and, in its severest forms, can be fatal.

 

October 4, 2010

Human Genome Sciences and Novartis have decided not to further develop an investigative biologic treatment...

ROCKVILLE, Md. Human Genome Sciences and Novartis have decided not to further develop an investigative biologic treatment for hepatitis C following the Food and Drug Administration’s decision to decline its approval, HGS said Tuesday.

 

HGS said it received a complete response letter from the FDA concerning the drug Zalbin (albinterferon alfa-2b). The FDA delivers a complete response letter to indicate that it has finished reviewing an application, but questions remain that preclude final approval.

 

 

August 18, 2010

The Food and Drug Administration has decided to expedite the review of an investigational drug...

July 12, 2010

A developer of a new drug for treating lupus has entered a supply agreement with...

June 16, 2010

An investigational drug for lupus that could become the first new treatment for the disease...

June 9, 2010

Human Genome Sciences has submitted an approval application for a treatment for lupus, development partner...